Outlook: The profit problem in antibiotic R&D Review uri icon

Overview

MeSH Major

  • Anti-Bacterial Agents
  • Biomedical Research
  • Drug Design
  • Drug Industry
  • Marketing
  • Research Support as Topic

abstract

  • Economists, a biomedical researcher and a business executive have formulated three contrasting proposals to address the shortfall in antibiotic R&D. Their proposals, which emphasize advance purchase contracts, not-for-profit research, and tax incentives, respectively, share some features with provisions in bills pending before the US Congress that could potentially reshape the R&D landscape for this essential class of drugs.

publication date

  • November 2005

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1038/nrd1878

PubMed ID

  • 16247440

Additional Document Info

start page

  • 887

end page

  • 91

volume

  • 4

number

  • 11